Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer

Código QR

Targeting MERTK and AXL in <i>EGFR</i> Mutant Non-Small Cell Lung Cancer

MERTK and AXL are members of the TAM family of receptor tyrosine kinases and are abnormally expressed in 69% and 93% of non-small cell lung cancers (NSCLCs), respectively. Expression of MERTK and/or AXL provides a survival advantage for NSCLC cells and correlates with lymph node metastasis, drug res...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dan Yan, H. Shelton Earp, Deborah DeRyckere, Douglas K. Graham
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	MERTK AXL TAM family receptor tyrosine kinase targeted therapy NSCLC Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f008783afb8b4deca24ca6395ea261cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors
por: Viola Hedrich, et al.
Publicado: (2021)

Immunohistochemical Evaluation and Clinicopathological Correlation of Mer and Axl Tyrosine Kinase TAM Receptors in Cutaneous Melanoma
por: Andrea Pontara, et al.
Publicado: (2020)

Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8<sup>+</sup> T Cells
por: Richard M. Powell, et al.
Publicado: (2021)

Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human Sertoli Cells
por: Daniel P. Strange, et al.
Publicado: (2019)

Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
por: Akiko Takahashi, et al.
Publicado: (2018)

Targeting AXL in NSCLC
por: Zaman A, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
por: Skye Montoya, et al.
Publicado: (2021)

Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
por: Yukari Tsubata, et al.
Publicado: (2021)

Effect of Epigallocatechin-3-Gallate on EGFR Signaling and Migration in Non-Small Cell Lung Cancer
por: Cristina Minnelli, et al.
Publicado: (2021)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sareshma Sudhesh Dev, et al.
Publicado: (2021)

Study of the Role of the Tyrosine Kinase Receptor MerTK in the Development of Kidney Ischemia-Reperfusion Injury in RCS Rats
por: Thomas Pelé, et al.
Publicado: (2021)

AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines
por: Samuel D. Zwernik, et al.
Publicado: (2021)

Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

The Role of Brain-Derived Neurotrophic Factor in Epileptogenesis: an Update
por: Xinyi Wang, et al.
Publicado: (2021)

Vitamin K Effects on Gas6 and Soluble Axl Receptors in Intensive Care Patients: An Observational Screening Study
por: Ulf Schött, et al.
Publicado: (2021)

Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis
por: Li-Wei Sun, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Clinical case of long-term use of osimertinib in the treatment of EGFR mutation-positive lung adenocarcinoma
por: Svetlana V. Odintsova, et al.
Publicado: (2020)

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
por: Raj Kumar Mongre, et al.
Publicado: (2021)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Elisabete Cruz Da Silva, et al.
Publicado: (2021)

IRF6, RYK, and PAX9 Expression in Facial Tissue of Children with Cleft Palate
por: Smane,Liene, et al.
Publicado: (2015)

Molecular targets in GI malignancies – A pathologist's perspective
por: Satyajit Pawar, et al.
Publicado: (2021)

Prognostic value and immunological role of AXL gene in clear cell renal cell carcinoma associated with identifying LncRNA/RBP/AXL mRNA networks
por: Yi Wang, et al.
Publicado: (2021)

Expanding the Disorder-Function Paradigm in the C-Terminal Tails of Erbbs
por: Louise Pinet, et al.
Publicado: (2021)

Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
por: Florian Janisch, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Nathaniel Wiest, et al.
Publicado: (2021)

Polimorfismo G691S, L769L y S836S del proto-oncogen RET no se asocian a mayor riesgo de cáncer medular tiroideo esporádico en pacientes chilenos
por: Wohllk G,Nelson, et al.
Publicado: (2005)

Lipid rafts: cell surface platforms for T cell signaling
por: MAGEE,TONY, et al.
Publicado: (2002)

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung Cancer
por: Xuan Zhou, et al.
Publicado: (2021)

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
por: Brazel D, et al.
Publicado: (2021)

MET Receptor Tyrosine Kinase Regulates Lifespan Ultrasonic Vocalization and Vagal Motor Neuron Development
por: Anna K. Kamitakahara, et al.
Publicado: (2021)

Tumores del estroma gastrointestinal (GIST), un particular tipo de neoplasia
por: Bórquez M,Pablo, et al.
Publicado: (2008)

ELEVATE-RR – first head-to-head trial of acalabrutinib versus ibrutinib in previously treated high risk chronic lymphocytic leukemia
por: Tatiana E. Bialik, et al.
Publicado: (2021)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)

Comparison of afatinib and osimertinib effect on overall survival in first-line drug treatment of EGFR-positive metastatic non-small cell lung cancer: network meta-analysis
por: Sergey V. Goryaynov
Publicado: (2021)

Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to <italic toggle="yes">Candida</italic> Species
por: Paige E. Negoro, et al.
Publicado: (2020)